Sangui Biotech International Stock Shares Owned By Insiders
SGBI Stock | USD 0.0002 0.00 0.00% |
Sangui Biotech International fundamentals help investors to digest information that contributes to Sangui Biotech's financial success or failures. It also enables traders to predict the movement of Sangui Pink Sheet. The fundamental analysis module provides a way to measure Sangui Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangui Biotech pink sheet.
Sangui |
Sangui Biotech International Company Shares Owned By Insiders Analysis
Sangui Biotech's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Sangui Biotech Shares Owned By Insiders | 13.03 % |
Most of Sangui Biotech's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangui Biotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 13.03% of Sangui Biotech International are shares owned by insiders. This is 14.16% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by insiders for all United States stocks is 29.14% lower than that of the firm.
Sangui Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangui Biotech's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sangui Biotech could also be used in its relative valuation, which is a method of valuing Sangui Biotech by comparing valuation metrics of similar companies.Sangui Biotech is currently under evaluation in shares owned by insiders category among its peers.
Sangui Fundamentals
Return On Asset | -0.64 | |||
Profit Margin | (1.27) % | |||
Operating Margin | (1.50) % | |||
Current Valuation | 1.68 M | |||
Shares Outstanding | 209.9 M | |||
Shares Owned By Insiders | 13.03 % | |||
Price To Earning | (18.33) X | |||
Price To Book | 46.44 X | |||
Price To Sales | 10.09 X | |||
Revenue | 69.19 K | |||
Gross Profit | 69.19 K | |||
EBITDA | (18.44 K) | |||
Net Income | (63.34 K) | |||
Cash And Equivalents | 30.47 K | |||
Total Debt | 48.9 K | |||
Debt To Equity | 0.05 % | |||
Current Ratio | 0.07 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (140.46 K) | |||
Beta | 0.22 | |||
Market Capitalization | 902.58 K | |||
Total Asset | 130.79 K | |||
Retained Earnings | (37 M) | |||
Net Asset | 130.79 K |
About Sangui Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangui Biotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangui Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangui Biotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.